151 related articles for article (PubMed ID: 35218397)
41. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.
Tallman MS; Hakimian D; Rademaker AW; Zanzig C; Wollins E; Rose E; Peterson LC
Blood; 1996 Sep; 88(6):1954-9. PubMed ID: 8822913
[TBL] [Abstract][Full Text] [Related]
42. [Successful induction and complete improvement of myelofibrosis and erythema nosodum with cladribine in a case of hairy cell leukemia].
Araki H; Matsunaga T; Murase K; Kuroda H; Kuribayashi K; Terui T; Niitsu Y
Gan To Kagaku Ryoho; 2004 Jun; 31(6):965-9. PubMed ID: 15222122
[TBL] [Abstract][Full Text] [Related]
43. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
44. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
[TBL] [Abstract][Full Text] [Related]
45. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
46. CD56-Positive Acute Myeloid Leukemia Following Treatment of Hairy Cell Leukemia with Cladribine - Report of 2 Cases and Review of the Literature.
Colovic N; Marisavljevic D; Kraguljac-Kurtovic N; Bogdanovic A; Gotic M
Arch Iran Med; 2019 May; 22(5):269-271. PubMed ID: 31256601
[TBL] [Abstract][Full Text] [Related]
47. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
48. [Hairy cell leukemia and pregnancy].
Al-Radi LS; Moiseeva TN; Smirnova SY; Shmakov RG
Ter Arkh; 2017; 89(7):99-104. PubMed ID: 28766548
[TBL] [Abstract][Full Text] [Related]
49. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Mhawech-Fauceglia P; Oberholzer M; Aschenafi S; Baur A; Kurrer M; Von Rohr A; Hsu-Schmitz SF; Wagner B; Delacretaz F; Hurwitz N;
Arch Pathol Lab Med; 2006 Mar; 130(3):374-7. PubMed ID: 16519567
[TBL] [Abstract][Full Text] [Related]
50. Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan.
Zahid MF; Mehdi MQ; Ali N
Hematol Transfus Cell Ther; 2019; 41(2):134-138. PubMed ID: 31084763
[TBL] [Abstract][Full Text] [Related]
51. Hairy cell leukemia: A decade long experience of North Indian Hematology Center.
Somasundaram V; Purohit A; Aggarwal M; Manivannan P; Mishra P; Seth T; Tyagi S; Mahapatra M; Pati HP; Saxena R
Indian J Med Paediatr Oncol; 2014 Oct; 35(4):271-5. PubMed ID: 25538404
[TBL] [Abstract][Full Text] [Related]
52. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases.
Hoffman MA
Med Oncol; 2011 Dec; 28(4):1537-41. PubMed ID: 20509009
[TBL] [Abstract][Full Text] [Related]
53. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
Rai KR
Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325
[TBL] [Abstract][Full Text] [Related]
54. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
55. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R; Arn K; Andres M; Pabst T; Baumann M; Novak U; Hitz F; Hess U; Zenhaeusern R; Chalandon Y; Mey U; Blum S; Rauch D; O'Meara Stern A; Cantoni N; Bargetzi M; Bianchi-Papina E; Rossi D; Passweg J; Lohri A; Berardi S; Li Q; Feller A; Stussi G
Blood Adv; 2020 Aug; 4(15):3699-3707. PubMed ID: 32777066
[TBL] [Abstract][Full Text] [Related]
56. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.
Ganzel C; Gatt ME; Maly A; Ben-Yehuda D; Goldschmidt N
Leuk Lymphoma; 2012 Jun; 53(6):1169-73. PubMed ID: 22035415
[TBL] [Abstract][Full Text] [Related]
57. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.
Piro LD; Ellison DJ; Saven A
Leuk Lymphoma; 1994; 14 Suppl 1():121-5. PubMed ID: 7820043
[TBL] [Abstract][Full Text] [Related]
58. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Juliusson G; Liliemark J
Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
[TBL] [Abstract][Full Text] [Related]
59. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
60. Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T; Levy I; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Dally N; Rouvio O; Shaulov A; Greenbaum U; Inbar M; Polliack A
Leuk Res; 2019 Jul; 82():24-28. PubMed ID: 31152919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
